Get started
Author

Lien Gheyle

Observed name: L. Gheyle
ORCID: 0009-0003-1491-0494
Observed ORCID: 0009-0003-1491-0494
OpenAlex ID: A5058442317
Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study
2016 · Erik Stroes, John R. Guyton, et al. · Journal of the American Heart Association · 102
PDF
The NK3 Receptor Antagonist ESN364 Suppresses Sex Hormones in Men and Women
2015 · Graeme L. Fraser, Steven Ramael, et al. · The Journal of Clinical Endocrinology & Metabolism · 79
Inflammatory parameters associated with systemic reactogenicity following vaccination with adjuvanted hepatitis B vaccines in humans
2019 · Wivine Burny, Arnaud Marchant, et al. · Vaccine · 75
PDF
Bioequivalence, safety and immunogenicity of BI 695501, an adalimumab biosimilar candidate, compared with the reference biologic in a randomized, double-blind, active comparator phase I clinical study (VOLTAIRE®-PK) in healthy subjects
2016 · Christopher Wynne, Mario Altendorfer, et al. · Expert Opinion on Investigational Drugs · 60
PDF
A phase I, randomized, proof‐of‐clinical‐mechanism study assessing the pharmacokinetics and pharmacodynamics of the oral PDE9A inhibitor BI 409306 in healthy male volunteers
2017 · Katja Boland, Viktoria Moschetti, et al. · Human Psychopharmacology Clinical and Experimental · 28
Effect of fermented milk containing Lactobacillus casei strain Shirota on constipation-related symptoms and haemorrhoids in women during puerperium
2014 · T. Sakai, H. Kubota, et al. · Beneficial Microbes · 26
Pharmacokinetics, Safety, and Tolerability of Fevipiprant (QAW039), a Novel CRTh2 Receptor Antagonist: Results From 2 Randomized, Phase 1, Placebo‐Controlled Studies in Healthy Volunteers
2015 · Veit J. Erpenbeck, Eva Vets, et al. · Clinical Pharmacology in Drug Development · 24
PDF
A randomized, crossover, placebo-controlled clinical trial to assess the sensitivity of the CRCDS Mini-Sim to the next-day residual effects of zopiclone
2015 · Arthur A. Simen, Cynthia Gargano, et al. · Therapeutic Advances in Drug Safety · 18
PDF
Abstract 18403: Effect of Dabigatran on the Ability to Generate Fibrin at a Wound site and its Reversal by Idarucizumab, the Antidote to Dabigatran, in Healthy Volunteers: An Exploratory Marker of Blood Loss
2014 · Joanne van Ryn, Michael Schmoll, et al. · Circulation · 17
Favorable human safety, pharmacokinetics and pharmacodynamics of the autotaxin inhibitor GLPG1690, a potential new treatment in COPD
2015 · Ellen Van der Aar, Liesbeth Fagard, et al. · 7
Safety, tolerability and pharmacokinetics of an oral competitive reversible CRTh2 antagonist, QAW039, in healthy subjects
2014 · Veit J. Erpenbeck, Eva Vets, et al. · European Respiratory Journal · 5
Fri0339 Long-term Efficacy of the Oral Selective Janus Kinase 1 Inhibitor Filgotinib in Psoriatic Arthritis: Week 52 Response Patterns in Individual Patients From an Open-label Extension (ole) Study (equator2)
2020 · D.D. Gladman, L.C. Coates, et al. · Annals of the Rheumatic Diseases · 4
PDF
Fri0343 Efficacy and Safety of Filgotinib, a Selective Janus Kinase 1 Inhibitor, in Patients With Active Psoriatic Arthritis: Subgroup Analyses From a Randomized, Placebo-controlled, Phase 2 Trial (equator)
2020 · P. Helliwell, F. Van den Bosch, et al. · Annals of the Rheumatic Diseases · 4
PDF
Abstract 1568: GLPG0187, a small molecule integrin antagonist, shows good safety and decrease in CTX levels in single ascending dose study
2010 · Giocondo Lorenzon, Lien Gheyle, et al. · Cancer Research · 4
Fri0344 the Long-term Effect of Treating Psoriatic Arthritis With the Janus Kinase 1-selective Inhibitor Filgotinib on Lipid Profiles: an Analysis of the Equator and Equator2 Trials
2020 · M.E. Husni, D.D. Gladman, et al. · Annals of the Rheumatic Diseases · 3
PDF
802 Safety and Efficacy of Ncx 6560 a Nitric Oxide (no)- Donating Atorvastatin in a First-into-man Randomised Double-blind Placebo- and Active-controlled Study
2011 · P. Pfister, J. Djian, et al. · Atherosclerosis Supplements · 2
Efficacy and safety of filgotinib in patients with active radiographic and nonradiographic axial spondyloarthritis: results from OLINGUITO, a phase 3 trial consisting of 2 randomised, placebo-controlled, double-blind, parallel-group studies
2026 · Xenofon Baraliakos, Walter P Maksymowych, et al. · Annals of the Rheumatic Diseases · 1
Pos1038 the Effect of Filgotinib on Enthesitis: 100-week Data From an Open-label Extension Study in Patients With Active Psoriatic Arthritis
2021 · P. Helliwell, L.C. Coates, et al. · Annals of the Rheumatic Diseases · 1
PDF
Pos0526 Sexual Function in Male and Female Patients With Rheumatoid Arthritis: a Post-hoc Analysis of the Finch Studies
2021 · L.F. Perez-Garcia, M. Micu, et al. · Annals of the Rheumatic Diseases · 1
PDF
Pos1049 Effect of Filgotinib on Pasdas: Drivers of Low and Very Low Activity up to Week 100
2021 · L.C. Coates, P.J. Mease, et al. · Annals of the Rheumatic Diseases · 1
PDF
Pos0905 Early Meaningful Improvements in Spinal Pain and Correlation With Other Clinical Outcomes in Patients Treated With Filgotinib for Radiographic Axial Spondyloarthritis: a Post Hoc Analysis of the Phase 2 Tortuga Trial
2025 · X. Baraliakos, F. Ciccia, et al. · Annals of the Rheumatic Diseases
Fonction sexuelle chez les hommes et les femmes atteints de polyarthrite rhumatoïde : une analyse post-hoc des études FINCH
2021 · L.F. Perez-Garcia, M. Micu, et al. · Revue du Rhumatisme
Pos1037 Correlation Between Skin Involvement, Joint Involvement and Enthesitis in Patients With Active Psoriatic Arthritis: Post-hoc Analysis of Equator/equator2
2021 · P.J. Mease, L.C. Coates, et al. · Annals of the Rheumatic Diseases
Efficacité à long terme du filgotinib (FIL) dans le traitement du rhumatisme psoriasique : résultats à S52 de l’étude d’extension en ouvert EQUATOR2
2020 · C. Tasset, D. Gladman, et al. · Revue du Rhumatisme
Effets à long terme sur le profil lipidique du filgotinib (FIL), inhibiteur spécifique de JAK1, dans le traitement du rhumatisme psoriasique : analyse des essais EQUATOR et EQUATOR2
2020 · C. Tasset, E. Husni, et al. · Revue du Rhumatisme
Works count: 28
Citation count: 461
H-index: 9
I10-index: 9
Year
Topic
Type